BCAL Diagnostics Limited (ASX:BDX)

Jayne Shaw is the Executive Chair and co-founder of BCAL Diagnostics. She is a qualified and registered nurse in the UK, and on arrival in Australia she became Director of Nursing and Chief Executive Officer of two private hospitals. Founding a consulting business, later acquired by Healthsouth, she co-founded Vision Group—an ASX-listed Ophthalmic Doctor equity model. With diverse roles on private healthcare boards, she co-owns Sydney Breast Clinic. Holding current board positions at The Citadel Group, Ellerston JAADE Australian Private Assets Fund, Mable Technologies, and Corum Group. Jayne also serves as a Non-Executive Director at Pinnacle Charitable Foundation and Prospection.

Jonathan, an Independent Non-Executive Director, brings over 30 years of global expertise in commercial, corporate governance, and law. He currently chairs ASX-listed entities, including Global Value Fund Ltd, Plato Income Maximizer Limited, and Spheria Emerging Companies Limited. Jonathan serves as a non-executive director for Kore Potash Limited on LSE, JSE, and ASX. His extensive background includes leadership roles at Meridian International Capital Limited and Herbert Smith Freehills. A Fellow of the Australian Institute of Company Directors, he previously chaired Future Generation Investment Company Ltd, Antipodes Global Investment Company Ltd, and Spicers Limited.

Dr Hurrell has developed and successfully commercialised multiple products and services in life sciences and diagnostics over a career in the industry spanning more than 35 years. He has developed and managed start-up and early-stage companies including successful life science companies based on university developed technologies. Most notably Dr Hurrell spent almost 7 years in managerial and executive roles with NYSE-listed, Fortune 500 clinical laboratory company Quest Diagnostics. Within Quest’s subsidiary Focus Diagnostics, he led the development and launch of more than 70 molecular diagnostics tests and successfully gained 510(k) approvals for 6 products. He also served as VP of Business Development at Quest Diagnostics.

David Darling is a highly credentialed leader and executive who brings a wealth of commercial experience to BCAL from his prior role as CEO of Pacific Edge, a NZX50 and ASX listed business focused on commercialising its bladder cancer diagnostics tests across global markets, with commercial operations in New Zealand, Australia, Singapore and the USA. Prior to Pacific Edge, Mr Darling held senior management positions with Fletcher Challenge. ​

Mr Darling has a background as a scientist with a specialty in genetics and has more than three decades of experience in developing and commercialising life sciences and biotechnology products.

Mark Burrows AO, with a distinguished global career in investment banking, transitioned into advocating private sector engagement for sustainable development and green finance evolution. Mark held senior advisory roles with UNEP, UNDP, The Green Finance Initiative in London, and the G20 Sustainability Group. Presently, he serves on the Asian Board of the Nature Conservancy, embodying his commitment to environmental initiatives and sustainable practices.

After 15 years in the NSW Parliament, including roles as Minister for Health and Deputy Leader of the Opposition, Ron forged a thriving consulting business in Health and Aged Care. Formerly co-owner and Managing Director of Sydney Breast Clinic, later sold to Healthscope, he now chairs the Sydney Local Health District and serves as Director on Westmead IVF.